Background The purpose of this study was to compare clinical outcomes of Erlotinib versus
Gefitinib in the treatment of Asian patients with exon 19 EGFR-mutant lung adenocarcinoma …

Objective Brain metastases occur in one-third of all non-small-cell lung cancer patients. Due
to restrictive transport at the blood–brain barrier, many drugs provide poor control of …

Objective: To investigate the relationship between the status of epidermal growth factor
receptor (EGFR) mutations and brain metastases in patients with lung adenocarcinoma …

Median survival of patients with brain metastases from nonsmall cell lung cancer (NSCLC) is
poor and more effective treatments are urgently needed. We have evaluated the efficacy of …

Purpose Brain metastasis (BM) is associated with impaired quality of life and increased
mortality. The study aimed to compare BM risk after erlotinib administration and …

Introduction Activating mutations in the epidermal growth factor receptor gene (EGFR)
predict for prolonged progression-free survival in patients with advanced non–small cell …

Introduction The efficacy of high-dose (1250 mg/d) gefitinib for the treatment of
leptomeningeal metastasis in a patient with lung cancer harboring a mutation in the …

Background Compared with standard chemotherapy, epidermal growth factor receptor
tyrosine kinase inhibitors (EGFR-TKIs) are more effective in patients with advanced non …

Background Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are
more effective in patients with advanced non-small-cell lung cancer (NSCLC) with EGFR …

Erlotinib and pemetrexed have been approved for the second-line treatment of non-small
cell lung cancer. Recent reports indicated that erlotinib and pemetrexed exerted synergistic …